Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vaxart, Inc. (VXRT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries that help explain the contents of each document in clear language. As a clinical-stage biotechnology company developing oral recombinant pill vaccines, Vaxart uses its filings to report on clinical progress, collaborations, listing status and material agreements that shape its vaccine platform and financial position.
Through Vaxart’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, investors can review detailed discussions of its oral vaccine programs for coronavirus, norovirus, influenza and HPV, as well as information on research and development spending, government contract revenue and risk factors. Current reports on Form 8‑K highlight specific events, such as the exclusive license and collaboration agreement with Dynavax Technologies Corporation for Vaxart’s oral COVID-19 vaccine candidate, updates on the BARDA-funded Project NextGen Phase 2b trial, lease terminations related to cost reduction efforts, and governance and listing developments.
For trading status, Vaxart’s 8‑K filings and the Form 25 filed by Nasdaq Stock Market LLC document the suspension and removal of the company’s common stock from Nasdaq and its quotation on the OTCQX Best Market under the symbol VXRT. These filings provide the official record of Vaxart’s transition from a national exchange to OTCQX and the conditions that led to delisting.
On this page, users can also monitor any registration statements, prospectus supplements and other capital markets filings that Vaxart uses to raise funds or register securities, as well as any future proxy materials related to corporate actions. Stock Titan’s AI tools summarize long forms such as 10‑K and 10‑Q, highlight key sections on clinical programs, government contracts and collaboration terms, and surface important items from 8‑Ks so that readers can quickly understand how each filing may relate to Vaxart’s oral vaccine development and trading status.
On October 8, 2025, Vaxart, Inc. disclosed that BARDA (through ATI) issued a Follow-Up Notice narrowing the scope of a Project Agreement to exclude "Paused Work." The company said ongoing activities will continue for the approximately 5,000 participants already enrolled in the Trial and that Vaxart will continue to receive funding to evaluate those participants. Vaxart stated it believes the Trial data from enrolled participants could provide useful insights and a foundation of evidence to potentially advance its COVID program. The filing clarifies these changes are furnished and not "filed" under Section 18, and it includes standard forward-looking statement language about risks and uncertainties.
Vaxart, Inc. reports that Nasdaq has decided to delist its securities after the company failed to meet conditions previously set by a Nasdaq Hearings Panel. Those conditions required shareholder approval of a reverse stock split by September 5, 2025, completion of the reverse split by October 6, 2025, and proof that the company met Nasdaq’s minimum bid price requirement. Vaxart withdrew its reverse stock split proposal on September 18, 2025, which left these conditions unmet.
Nasdaq’s Office of the General Counsel sent a letter on September 19, 2025 stating that Vaxart’s securities will be delisted. Trading of Vaxart’s common stock on Nasdaq has already been suspended since the open of trading on July 8, 2025. The company’s common stock is currently quoted on the OTCQX® Best Market under the symbol VXRT, meaning its shares continue to trade but no longer on a national securities exchange.
Vaxart, Inc. informed investors that a previously adjourned special meeting of stockholders, originally convened on September 5, 2025 and reconvened for September 19, 2025, will not be reconvened because the company withdrew the listed proposal from stockholder consideration on September 18, 2025. The proposal had been included in a proxy statement filed on August 6, 2025 and the meeting was adjourned earlier to give stockholders additional time to vote. The filing states only the withdrawal decision and that the company will not reconvene the adjourned meeting; no additional rationale, future steps, or timing for any alternative actions were provided.
Vaxart, Inc. faces an organized shareholder opposition: a group calling itself the Concerned Vaxart Stockholders issued an exempt solicitation press release dated September 18, 2025 urging holders to vote AGAINST the proposed reverse stock split.
The group notes the reverse split was overwhelmingly rejected at the June 13, 2025 annual meeting (twice adjourned) and cites the originally scheduled September 5, 2025 special meeting as further evidence of shareholder resistance. The petitioners criticize recent board actions and request constructive dialogue and governance reforms rather than symbolic appointments.